Nitric oxide mediates fluid accumulation during cardiopulmonary bypass  by Wehberg, Kurt E. et al.
NITRIC OXIDE MEDIATES FLUID 
Kurt E. Wehberg, MD a 
Andrew H. Foster, MD b 
Robert M. Wise, MS u 
Joseph S. McLaughlin, MD b 
Martha J. Brunner, PhD a 
ACCUMULATION DURING CARDIOPULMONARY BYPASS 
Fluid accumulation during cardiopulmonary bypass may be related to the 
production of endogenous vasoactive substances. We investigated the role 
of nitric oxide in mediating fluid accumulation during cardiopulmonary 
bypass. Normothermic ardiopulmonary bypass was carried out for 3 hours 
in male Sprague-Dawley rats with constant, nonpulsatile flow and hemodi- 
lution. Fluid accumulation (rate of change of external reservoir volume) 
was measured under three experimental conditions: saline solution control 
(n = 8), L-arginine infusion (n = 6), and N-nitro-L-arginine methyl ester 
infusion (n = 6). At the end of the experiments, body weight and organ 
wet/dry ratios were examined. Percentage w ight gain was 77% greater in 
the N-nitro-L-arginine methyl ester group and 23% less in the L-arginine 
group compared with control values. Fluid accumulation was increased 
with N-nitro-L-arginine methyl ester after 30 minutes (p < 0.01) and 
reduced with L-arginine after 120 minutes (p < 0.01) compared with control 
animals. Water content was significantly decreased in the heart, lung, skin, 
muscle and peritoneum in rats receiving L-arginine. These data suggest 
that endogenous nitric oxide plays an important role in minimizing fluid 
accumulation during cardiopulmonary bypass. (J Thorac Cardiovasc Surg 
1996;112:168-74) 
F luid accumulation is a significant problem in all patients undergoing cardiopulmonary bypass 
(CPB). This phenomenon has been characterized as 
a "whole-body inflammatory response" and may be 
related to the production and release of vasoactive 
substances that alter capillary permeabil ityJ -5 Nitric 
oxide (NO), which is produced in and released from 
the vascular endothelium, may play a key role in 
mediating this response, l' 6, 7 
NO is synthesized from L-arginine by the enzyme 
NO synthase, which may be competitively inhibited 
by L-arginine analogs such as N-nitro-L-arginine 
methyl ester (L-NAME). s The physiologic functions 
of NO include the maintenance of vasodilatory 
tone, 9 the mediation of cytokine release,  and the 
modulation of microvascular permeabil ityJ ° The 
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function of NO during CPB, however, remains 
unknown. 
The purpose of this study was to determine 
whether NO mediates fluid accumulation during 
CPB. In a rat model, we measured the rate of fluid 
accumulation during a 3-hour interval of CPB. The 
production of NO was either stimulated by L-argi- 
nine or inhibited by L-NAME. 
Methods 
Surgical preparation. Acute experiments were per- 
formed on healthy male Sprague-Dawley rats (Charles 
River Laboratories, Inc., Wilmington, Mass.) weighing 
420 _+ 20 gm. Experiments were conducted according to 
the "Guide for the Care and Use of Laboratory Animals" 
prepared by the Institute of Laboratory Animal Resources 
and published by the National Institutes of Health (NIH 
Publication No. 86-23, revised 1985). The protocol was 
approved by the Institutional Animal Care and Use 
Committee of the University of Maryland at Baltimore. 
Rats were anesthetized with intraperitoneal sodium 
pentobarbital (50 mg/kg) and mechanically ventilated 
(Harvard Rodent Ventilator, model 683; Harvard Appa- 
ratus, Inc., South Natick, Mass.) through a tracheostomy. 
Additional sodium pentobarbital was given intravenously 
as needed (5 mg/kg) to maintain anesthesia throughout 
the experiment. The femoral artery and vein were cannu- 
lated to measure mean distal aortic pressure (MAP) and 
femoral venous pressure (FVP), respectively. Catheters 
were made of polyvinyl and Tygon tubing (Dural Plastics; 
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Auburn, Australia) with an inner diameter of 0.5 mm and 
an outer diameter of 0.8 ram. After femoral catheteriza- 
tion, tracheostomy, and median sternotomy, the animals 
were heparinized (1000 units) and equilibration was al- 
lowed for 15 minutes before the treatment protocol was 
begun. 
CPB was instituted under conditions of constant non- 
pulsatile flow, constant hemodilution, and normothermia. 
The pump-oxygenator unit (Fig. 1) consisted of a Master- 
flex (partially occlusive) roller pump (Cole-Parmer Instru- 
ment Co., Chicago, Ill.) and a noncompliant hollow-fiber 
membrane oxygenator (Travenol Laboratories, Inc., 
Deerfield, Ill.). Oxygenation was delivered at 250 ml/min 
with an inspired oxygen fraction of 50% to 75%. The total 
volume of the pump-oxygenator unit and tubing was 46 
ml. The system was primed with 30 ml heparinized, 
homologous whole blood obtained from donor rats on the 
same day as the experiment. Venous return was drained 
by gravity into an open 60 ml reservoir from a miniatur- 
ized two-stage cannula placed through the right atrial 
appendage into the inferior vena cava (Varflex Syntholvar 
Tubing, 1.8 mm inner diameter; Rome, N.Y.). This system 
allowed optimal decompression of the right side of the 
heart. Oxygenated blood was filtered (40 txm Pall Corp., 
Biomedical Products Div., Glen Cove, N.Y.) and then 
returned to the animal through an aortic cannula (Varflex 
Syntholvar, 1.4 mm inner diameter) that was placed 
through the left ventricular apex into the ascending aorta 
just distal to the aortic valve. The aortic cannula was 
anchored by a purse-string suture placed around and the 
apex of the heart. This inflow system bypassed the left 
ventricle and allowed any pulmonary venous and left atrial 
blood (although minimal) to be suctioned from the chest 
and returned to the venous reservoir. This technique also 
allowed coronary artery peffusion, as evidenced by the 
heart's continued beating throughout the experiment. 
Fluid accumulation was measured as the rate of change 
of volume in the extracorporeal venous reservoir. This 
method, which has been described previously 11 but min- 
iaturized, is an accurate stimation of fluid accumulation 
in the animal. The principle of this method is that any 
losses of volume in the external venous reservoir eflect 
reciprocal increases in volume in the animal. This princi- 
ple holds true because the pump-oxygenator unit and 
tubing (closed system) are noncompliant. Evaporative 
losses and potential losses from the heat exchanger were 
deliberately controlled. Volume changes in the reservoir 
were measured by a pressure transducer (model 807; 
Beckman Instruments, Spinco Div., Palo Alto, Calif.) at 
the base of the external reservoir. Pressure was directly 
proportional to the height of the blood in the reservoir, 
and changes as small as 1 ml/min were accurately de- 
tected. Throughout he course of CPB, reservoir volume 
continually declined, reflecting fluid accumulation i the 
rat. Fluid (either homologous blood or lactated Ringer's 
solution) was replaced as needed to prevent he reservoir 
from emptying. 
Factors known to affect fluid accumulation were held 
constant. Hemodilution, one of the most important fac- 
tors in fluid accumulation, ~2was held constant by adding 
homologous blood to the external reservoir if hematocrit 
levels fell by 2%. Hematocrit levels were analyzed at 
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Fig. 1. CPB pump-oxygenator unit provides constant 
nonpulsatile flow and oxygenation through hollow-fiber 
membrane. Total volume of extracorporeal circuit is 46 
ml. SVC, Superior vena cava; IVC, inferior vena cava. 
30-minute intervals and were maintained at 13 ± 1.2%. 
Pump flow was maintained at a constant level of 125 ml. 
kg- 1. min- 1. Flow and hemodilution were predetermined 
to provide adequate tissue oxygenation i the rat during 
CPB on the basis of several metabolic parameters, includ- 
ing arterial pH (maintained at 7.37 ± 0.02), venous 
oxygen saturation (range 70% to 86%), and arterial 
oxygen tension (maintained at 209 ± 12 mm Hg). Osmo- 
lality remained constant throughout the experiments (274 
± 2 mmol/L before operation to 279 ± 9 mmol/L at 180 
minutes, with no significant change). Resistance in the 
tubing of the venous outflow tract, an important determi- 
nant of venous hydrostatic pressure, could also affect fluid 
accumulation. The height of the venous outflow cannula 
was therefore held constant at 10 cm below the level of the 
right atrium to maintain right atrial pressure at a constant 
level. Blood drained by gravity into the venous reservoir 
below. Body temperature was maintained at between 36 ° 
to 38 ° C by a heating blanket under the animal and a 
heating lamp above the animal. 
Protoeo|. Rats were randomly assigned to three treat- 
ment groups. Control animals (n = 8) received a 3 ml 
saline solution bolus (vehicle control) 15 minutes before 
initiation of CPB. Animals in the L-arginine group (n = 6) 
received L-arginine hydrochloride (Sigma Chemical 
Company, St. Louis, Mo.) as an intravenous bolus of 150 
mg/kg 15 minutes before CPB and an infusion of 
30 mg • kg -1 • hr -1 during CPB. Animals in the L-NAME 
group (n = 6) received L-NAME (Sigma) as a bolus of 30 
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Fig. 2. Fluid accumulation during CPB. Significant differences between control and L-NAME groups (p < 
0.01) at specific time points represented by asterisks; significant differences between control and L-arginine 
(p < 0.01)represented byplus signs. 
mg/kg before CPB and an infusion of 1 mg • kg-1. hr-1 
during CPB. 
CPB was maintained for 3 hours. Fluid uptake, femoral 
venous pressure, and MAP were measured at 0, 15, 30, 60, 
90, 120, and 180 minutes. Data points represent he 
average level during the last 2 minutes of each time 
interval. The time designated as -30 minutes represents 
baseline data before the experimental drug was given, 
-15 minutes represents he time at which the bolus of the 
experimental drug was given and the infusion was started, 
and 0 minutes represents he time at which the oxygenated 
blood was initiated through the aortic cannula. To evalu- 
ate fluid uptake, MAP, and FVP within each experimental 
group as functions of CPB time, comparisons were made 
between the original data point (e.g., for fluid uptake 
measurement the first data point for L-NAME was at 15 
minutes, whereas for FVP and MAP the first data points 
were at -30 minutes) and successive data points were 
within the experimental group. After the final measure- 
ment at 180 minutes, the animal was killed and its 
postoperative body weight was recorded. Blood and in- 
traluminal contents were r moved from organs before 
post mortem wet weights were obtained. The organs were 
then dried at 60°C for 24 hours and reweighed (dry 
weight) for the calculation of wet/dry ratios (wet weight 
minus dry weight divided by dry weight, expressed as 
milliliters of fluid per gram of tissue). Organ weights of 
animals undergoing CPB were compared with those of 
animals who underwent anesthesia, median sternotomy, 
heparinization, and constant hemodilution without CPB 
for 3 hours ("sham-operated group," n = 6). 
Statistical analyses. All data are expressed as mean +- 
standard error of the mean. Analysis of variance with 
repeated measures was used to evaluate differences in 
fluid accumulation, weight gain, and arterial and venous 
pressures as effects of time (response) and treatment 
group (control, L-arginine, and L-NAME groups). The 
Newman-Keuls test for individual differences was used to 
determine differences within groups. Organ weights were 
compared between treatment groups by means of a one- 
way analysis of variance. Significant differences were 
noted at p < 0.05. 
Results 
Fig. 2 illustrates the rate of fluid accumulation 
(ml • kg -1 • rain -1) during 3 hours of CPB. The rate 
of fluid accumulation was significantly greater in rats 
with NO inhibition (L-NAME) than in control rats 
after 30 minutes (p < 0.01). The rate of fluid 
accumulation in the L-arginine group was signifi- 
cantly less than in the control group after 120 
minutes (p < 0.01). The average rate of fluid 
accumulation through 3 hours was significantly 
greater (p < 0.01) in the L-NAME group (8.1 -_+ 2.1 
ml • kg -1 • rain -1) than in the control group (5.0 _+ 
0.4 ml • kg -1 • rain -1) and was significantly less (p < 
0.001) in the L-arginine group (3.0 - 0.5 ml • kg -1 • 
rain- l) .  Fluid accumulation as a function of time 
was significantly increased after 120 minutes in the 
control group (p < 0.05) and significantly increased 
after 30 minutes in the L-NAME group (p < 0.01). 
Fluid accumulation as a response to time was not 
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Fig. 3. Percentage weight gain after 3 hours of CPB. Note that weight gain was significantly less with 
L-arginine (p < 0.05 vs control, represented byplus sign) and greater with L-NAME (p < 0.01 vs control 
represented by asterisk). 
Table L Hemodynamic data during CPB: role of nitric oxide 
MAP (mm Hg) FVP (ram Hg) 
Time (min) Control L-Arginine L-NAME Control L-Arginine L-NAME 
--30 85.6 --+ 8.2 78.3 +-- 5.9 82.0 --+ 5.9 2.2 + 0.6 1.1 + 0,3 1.8 ± 0.9 
--15 85.0 --+ 8.0 71.7 ± 9.4 112.0 ± 4.9* 2.6 + 0.7 1.0 ± 0.3? 1.7 --+ 0.9 
0 72,0 +-- 12.1 90.0 ± 14.9 138.3 ± 22.9* 4.2 + 1.1 1.2 + 0.2t 3.0 --+ 1.1 
15 60,0 +-- 12.0 105.0 + 17.4 139,0 ± 21.6" 4.4 ----- 1.1 0.9 ± 0.3? 3.9 +-- 1.2 
30 64.4 + 12.4 78.3 ± 17.9 107.0 ± 25.1" 3.9 ± 0.8 1.9 ± 0.3? 4.9 +-- 1.2 
60 73.3 ± 13.4 65.0 --+ 20.7 93.0 --+ 16.4 4.7 ± 0.6 1.6 ± 0,6? 9.3 ± 1.6" 
90 93.6 +-- 15.6 64.2 --+ 27.9? 93.0 +-- 10.6 5.2 ----_ 1.1 2.3 + 0.4? 10,4 ± 1.3" 
120 112.6 +-- 16.6 64.7 --+ 24.4? 98.3 -- 10.2 7.7 ± 1.1 2.7 + 0.7? 10.0 ± 2.7* 
180 117.9 --+ 5.4 67.5 ± 25,8? 90.0 ± 15.8 7.4 + 1.4 2.9 ± 1.27 12.0 --+ 2.0* 
*Significant difference between control and L-NAME groups. 
?Significant difference between control and L-arginine groups. 
significant in the L-arginine group. Percentage 
weight gain (Fig. 3) was also significantly greater 
with L-NAME (p < 0.01) and significantly less with 
L-arginine (p < 0.01) than control values. 
Hemodynamic parameters during CPB are shown 
in Table I. In the control group, MAP decreased 
rapidly after the initiation of bypass (p < 0.01, -15 
minutes vs 15 minutes), returned to baseline l vels, 
and was not significantly increased with respect o 
time after 30 minutes. In the L-NAME group, MAP 
was significantly elevated compared with control 
values during the first 30 minutes of CPB (p < 0.01). 
MAP was not different from preoperative levels 
after 30 minutes, however, nor was it significantly 
different from control values after 30 minutes. In the 
L-arginine group, MAP was significantly decreased 
compared with control values after 90 minutes (p < 
0.01). The response of MAP to time in the L- 
arginine group was not significant. FVP was signif- 
icantly increased in the L-NAME group after 60 
minutes (p < 0.001)and ecreased in the L-arginine 
group compared with the control group ( < 0.01) at 
all time points except for the pre-CPB time points 
( -15 minutes and -30 minutes). The response to 
FVP as a function of time was significant in the 
L-NAME group after 60 minutes (p < 0.001) but was 
not significant in the L-arginine or control groups. 
Organ wet-dry ratios normalized for tissue weight 
after 3 hours CPB are listed in Table II. Fluid 
accumulation was increased compared with that in 
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Table II. Organ wet~dry atios (normalized for weight) after 3 hours of CPB 
Organ Sham (no CPB) Control (CPB) L-NAME (CPB) c-Arginine (CPB) 
Heart 3.49 + 0.16 3.95 -+ 0.15' 4.16 _+ 0.14 3.58 ± 0.09t 
Lung 4.14 ± 0.36 6.46 -+ 0.20* 6.04 ± 0.20 5.54 -+ 0.30? 
Brain 2.95 + 0.28 4.01 ± 0.13" 3.64 + 0.21 3.84 ± 0.20 
Kidney 2.98 ± 0.17 4.43 _+ 0.08* 4.53 ± 0.19 4.53 ± 0.11 
Liver 2.22 ± 0.01 2.49 _+ 0.21 2.73 ± 0.29 2.26 -+ 0.13 
Spleen 3.16 + 0.13 3.85 + 0.29* 3.62 _+ 0.11 4.60 ± 0.82 
S. Bowel 2.85 ± 0.12 3.97 ± 0.37* 3.93 ± 0.12 3.91 -+ 0.26 
Colon 2.62 _+ 0.20 8.76 ± 0.71" 8.17 _+ 0.44 8.70 -+ 0.64 
Muscle 2.79 ± 0.14 3.17 ± 0.19 3.96 ± 0.21:~ 3.49 _+ 0.20 
Skin 1.47 ± 0.05 1.47 _+ 0.35 2.70 ± 0.24:~ 2.41 ± 0.15 
Data expressed in milliliters of fluid per gram of tissue. 
*Significant difference between control and sham operated groups. 
?Significant difference between control and L-arginine groups. 
:~Significant difference between control and h-NAME groups. 
the sham-operated group in all organs of control 
animals except skin, muscle, and liver. Although 
CPB itself had no effect on fluid accumulation i
skin and muscle, inhibition of NO by L-NAME 
markedly increased water content in these organs. 
Organ fluid accumulation was significantly de- 
creased in the L-arginine group compared with the 
control group in the heart, lung, skin, and muscle. 
To estimate the approximate sensible (ascites) and 
insensible fluid losses, we compared the total amount 
of fluid given through 3 hours to the total weight 
gained. If more fluid was given than weight gained, this 
amount should represent insensible plus sensible 
losses. The control group had 71 ± 13 ml fluid loss, the 
L-NAME group had 230 ± 26 ml, and the L-arginine 
group had 15 ± 7 ml sensible and insensible losses. 
These data were consistent with our clinical observa- 
tion that animals receiving L-NAME had massive 
ascites and those receiving L-arginine had virtually no 
ascites. 
Discussion 
CPB may be associated with massive fluid accu- 
mulation. ~Our data show that systemic nhibition of 
the endogenous NO system by L-NAME leads to 
increased fluid accumulation, whereas enhancement 
of NO synthesis by L-arginine leads to reduced fluid 
accumulation during CPB. Accordingly, percentage 
weight gain increases with L-NAME and decreases 
with L-arginine. These results suggest that endoge- 
nous NO plays an important role in mediating fluid 
accumulation during CPB. 
The release of vasoactive substances during CPB 
has been well documented. Endothelin-l, 3' 4 prosta- 
glandin E 2 and prostacyclin, I3 interleukin-1, 2 brady- 
kinin, 5 and complement C3a and C5a 14 levels have 
been shown to be increased uring CPB. These 
substances interact with the endothelium to cause 
marked inflammatory responses, which lead to 
edema formation and fluid accumulation. 1 NO, 
which is produced and released by the endothelium, 
has not yet been previously described as a modula- 
tor of fluid accumulation during CPB. 
Fluid accumulation is directly proportional to the 
duration of CPB. 11 In the control and L-NAME 
groups in this study, fluid accumulation i creased 
progressively with time. The control animals had 
significant fluid accumulation asa function of time 
after 120 minutes, whereas animals receiving L- 
NAME had increased fluid accumulation after 30 
minutes. More important, animals in the L-arginine 
group did not have increased fluid accumulation 
after 120 minutes, suggesting that NO stimulation 
minimized the progressive fluid accumulation. 
These findings suggest that NO may be an important 
factor in preventing excessive fluid accumulation at
longer CPB durations. 
In our study, L-NAME caused marked elevations 
in FVP. It is well accepted that venous capacitance 
is decreased uring and early after CPB. 15 Sup- 
pressed NO formation could be a mechanism 
through which decreased venous capacitance o curs 
during CPB. This phenomenon is supported by 
Glick and associates, ~6who demonstrated a dose- 
dependent increase in mean systemic filling pressure 
and reduction in venous capacitance with increasing 
doses ofNG-monomethyl-L-arginine (L-NMMA), an 
inhibitor of NO like L-NAME. Furthermore, our 
additional findings of significant reductions in FVP 
with L-arginine, which promotes NO formation, 
confirms that NO decreases venous tone during 
CPB. These results and those of previous studies 
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suggest that NO may play a crucial role in decreas- 
ing venous tone during CPB. 
The mechanism by which NO mediates fluid 
accumulation during CPB may be related to its 
action on hydrostatic pressure in the arterial and 
central venous system and possibly on lymphatic 
drainage. MAP was significantly elevated with L- 
NAME only early in CPB. Because MAP was not 
significantly increased with L-NAME (compared 
with control values) in late CPB, the hydrostatic 
effects of MAP may not be the primary determi- 
nants of luid accumulation i late CPB. On the 
contrary, increased fluid accumulation i  the L- 
NAME group in late CPB may be a direct result of
the significantly elevated venous hydrostatic pres- 
sure. Finally, the increased fluid accumulation in the 
L-NAME group may be related to NO's ability to 
modulate lymphatic drainage, which has been sug- 
gested by recent studies. 17 Our concomitant findings 
of increased fluid accumulation and marked eleva- 
tions in FVP at longer CPB durations uggest that 
NO is important in minimizing excessive fluid loss by 
its vasodilatory actions on the venous bed. 
Another mechanism by which fluid accumulation 
is increased uring CPB could be through NO's 
effect on microvascular permeability. Kubes and 
Granger 1° recently demonstrated that inhibition of 
NO production by L-NAME leads to an increase in 
microvascular permeability in the small intestine of 
the cat. They also showed that L-NAME increases 
precapillary and postcapillary esistance, although it
does not change net capillary pressure, suggesting 
that NO affects permeability alone without changes 
in capillary pressure. Furthermore, they found that 
L-arginine prevented the increase in microvascular 
permeability and concluded that NO plays an im- 
portant role in minimizing loss of fluid from the 
vasculature. Our results upport his conclusion and 
suggest hat NO may be critically important in 
maintaining capillary integrity during CPB. 
Recent evidence suggests hat NO may contribute 
to the inflammatory esponse and edema formation 
in specific organs. In the small bowel of the cat, 
inhibition of NO by L-NAME causes arapid leakage 
of fluid out of the vasculature and into the intersti- 
tial space) ° We have shown that organ fluid accu- 
mulation is increased as a response to CPB alone 
(control group) in almost all organs except skin, 
muscle, and liver. Organ water content in the skin 
and muscle was markedly increased in the L-NAME 
group. Another interesting observation we found 
was that animals receiving L-NAME had massive 
ascites during CPB, whereas the animals receiving 
L-arginine had virtually no ascites. This suggests hat 
NO metabolism in the endothelium of mesenteric 
vasculature is important in minimizing ascites and 
sensible fluid loss during CPB. 
Fluid accumulation i  human patients during 
CPB is variable and has been estimated at between 
1 and 2.5 L during the 1- to 3-hour CPB time, 12 
which yields an average rate of accumulation of 
approximately 0.5 to 1.0 ml • kg -1 • rain -1. Similar 
rates have been found in normotensive dogs under- 
going CPB, although the rate was increased fivefold 
in hypertensive dogs. 11 The quantitative rate of fluid 
uptake (ml • kg-1. rain-1) in the control rats in our 
study is higher than in previous tudies. Differences 
in levels in our study may be explained by the 
moderate to extreme hemodilution to13% (as com- 
pared with 15% to 25% in human beings and no 
hemodilution in the dog study) and the higher 
resistance in the venous outflow tubing because of 
its smaller diameter to accommodate the rat atrium 
(1 to 2 mm). Additionally, age differences (3-month- 
old rats vs 2- to 3-year-old dogs vs 60-year-old 
human patients) may account for quantitative dif- 
ferences in rates of fluid accumulation. I  any case, 
differences in fluid accumulation within our study 
were attributed to changes in treatment protocol. 
In summary, we have demonstrated that the en- 
dogenous NO system is an important mediator of 
fluid accumulation during CPB. This vasoactive 
substance appears to minimize whole-body fluid 
accumulation during CPB and may play an impor- 
tant role in preventing ascites as well as in reducing 
fluid content in the heart, lung, skin, and muscle 
during CPB. This study suggests that therapeutic 
modalities that enhance ndogenous NO produc- 
tion may be beneficial in reducing whole-body and 
specific organ fluid accumulation during CPB. 
Specific mechanisms through which NO mediates 
fluid accumulation during CPB remain to be 
elucidated. 
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